Vienna (ots/PRNewswire) - CDI is one of the top ten hospital-acquired infections (HAIs) in European Hospitals[1] and is estimated to be three times as deadly as MRSA[2],[3] Data released at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017 demonstrate the impact of CDI on the ...
Orascom Development Holding AG
EQS Group-Ad-hoc: Orascom Development Holding AG / Key word(s): Final Results/Final Results Orascom Development Holding AG: Enhanced operational performance across all destinations yet bottom line results were impacted by FX losses derived from its Egyptian largest subsidiary Orascom Hotels & Development (OHD) ...
Bagsværd, Denmark (ots/PRNewswire) - Canada first country to launch Fiasp® This material is intended for global medical media only. For journalistic assessment and preparation before publication. Today, Novo Nordisk announced that Fiasp®, a new, fast-acting mealtime insulin for the treatment of diabetes in ...
Shire Pharmaceuticals Group Plc
Zug, Switzerland (ots/PRNewswire) - This Press Release is intended for Global Use If approved, Natpar would be the first licensed recombinant parathyroid hormone in Europe for the management of chronic hypoparathyroidism, the only endocrine-deficiency disorder with no hormone treatment[1] Shire plc (LSE: SHP, ...
Aachen / Pisa (ots) - Grünenthal receives Breakthrough Therapy Designation from U.S. FDA for neridronic acid for the treatment of complex regional pain syndrome (CRPS), a debilitating orphan disease with high medical need - Neridronic acid is the first investigational medicine to receive Breakthrough Therapy ...
EQS Group-Ad-hoc: EEII AG / Key word(s): Change of Personnel/Miscellaneous EEII AG: Appointment of new CEO and new Advisor 12-Dec-2016 / 17:38 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR 529059 12-Dec-2016 CET/CEST ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media - If approved by the FDA, avelumab, an investigational immunotherapy, could be the first treatment indicated for patients with metastatic Merkel cell carcinoma (MCC) - Avelumab has previously received FDA Breakthrough Therapy and Fast ...
Montreal (ots/PRNewswire) - Network performance assurance provider teams up with Facebook, telcos, tech companies, and other vendors to assure reliable, high-quality internet & telecom services access worldwide Accedian (http://www.accedian.com), the end-to-end network performance experts, announced today that it has joined the Facebook-backed Telecom Infra Project (https://telecominfraproject.com/) (TIP) as a member ...
Vancouver, British Columbia (ots/PRNewswire) - After Four Seasons and Twelve Episodes Filmed Across the Globe, A Skier's Journey Comes Home to British Columbia in its Final Episode Today, A Skier's Journey, the globally-acclaimed short film series, releases its final episode titled Coming Home, on http://www.askiersjourney.com. Launched in 2010 and directed by the ...
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Results from a study comparing the pharmacodynamics of Tresiba® (insulin degludec) with insulin glargine U300 in people with type 1 diabetes were presented ...
Paris (ots/PRNewswire) - - Toujeo® provides a flatter profile than insulin degludec with less within-day fluctuations - Sanofi (http://www.sanofi.com) presented today the full results of a pharmacokinetic / pharmacodynamic (PK/PD) study with Toujeo® (insulin glargine 300 Units/mL) and insulin degludec 100 Units/mL ...
Vienna (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstract: 69477 New data from the first health-related quality of life (HRQL) study related to post-meal or postprandial glucose (PPG) control, show that poor PPG control ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media - If approved, avelumab, an investigational anti-PD-L1 IgG1, could be the first treatment indicated for patients with metastatic Merkel cell carcinoma - The Marketing Authorization Application is based on Phase II data from the ...
Vancouver, British Columbia (ots/PRNewswire) - Recovered from a life-threatening brain injury, artist Jordan Manley creates three final films with skiers Chad Sayers and Forrest Coots in Iran and China, culminating in a special homecoming to British Columbia A Skier's Journey, the globally-acclaimed short film series is returning for its fourth and final season this fall. Directed by the celebrated Canadian filmmaker and ...
Shire Pharmaceuticals Group Plc
Lexington, Massachusetts (ots/PRNewswire) - Labeling Update Based on Maintenance of Efficacy Data from a 38-Week Phase 3 Study For U.S. Audiences Only - Shire plc (LSE: SHP, NASDAQ: SHPG) announces an update to the Vyvanse® (lisdexamfetamine dimesylate) labeling to include information regarding the approval of a ...
Teva Pharmaceutical Industries Ltd.
Amsterdam (ots/PRNewswire) - Approval of hybrid high-dose fluticasone/salmeterol maintenance treatment for people living with severe asthma and COPD, delivered via the award-winning Spiromax® inhaler to help patient usability Teva Pharmaceutical Industries Ltd., announced today that it has received EU Marketing Authorization for Aerivio Spiromax® ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK-based media ESMO Abstract # Avelumab: 777PD, 7775PD, 1154P, 842TiP, 844TiP; Erbitux: 527P, 491P, 967P, 994P; Tepotinib: 1257P, 1287TiP, 1292TiP - Merck KGaA, Darmstadt, Germany, to feature new research from marketed and pipeline compounds - Preliminary results from combination study with avelumab in renal cell ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media ESMO Abstract # Avelumab: 777PD, 775PD, 1154P, 842TiP, 844TiP; Erbitux: 527P, 491P, 967P, 994P; Tepotinib: 1257P, 1287TiP, 1292TiP - Merck to feature new research from marketed and pipeline compounds - Preliminary results from combination study with avelumab in renal cell carcinoma, and ...
Paris (ots/PRNewswire) - - Benefits on adherence and HbA1c to be validated in a real-world setting - Sanofi (http://www.sanofi.com) announced today that adults with type 2 diabetes treated with Toujeo® (insulin glargine 300 Units/mL) experienced a consistently lower rate of confirmed or severe hypoglycemia both at ...
Munich, Germany (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today presented data showing the odds of reaching fasting plasma glucose (FPG) targets without hypoglycaemia and weight gain were significantly ...
Munich (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly improved glycaemic ...
EQS Group-Ad-hoc: Kardex AG / Key word(s): Half Year Results Kardex AG: Continued profitable growth for the Kardex Group 11.08.2016 / 06:30 Release of an ad hoc announcement pursuant to Art. 53 KR. 491247 11.08.2016 ...
http://resources.euroadhoc.com/us/15p7kqOm company: Rosenbauer International AG Paschingerstrasse 90 A-4060 Leonding phone: +43(0)732 6794 568 FAX: +43(0)732 6794 89 mail: ir@rosenbauer.com WWW: www.rosenbauer.com sector: Machine Manufacturing ISIN: AT0000922554 indexes: WBI, ATX Prime stockmarkets: free trade: ...
EQS Group-Ad-hoc: NEW VALUE AG / Key word(s): Final Results NEW VALUE AG: Annual Result 2015/16 (as of March 31, 2016) 23.06.2016 / 20:00 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement. 474009 23.06.2016 ...
Axonics Modulation Technologies, Inc.
Irvine, California (ots/PRNewswire) - Post-market Clinical Study Evaluates Axonics Miniaturized, Rechargeable System for Overactive Bladder Patients Axonics Modulation Technologies, Inc., the developer of the first rechargeable implantable Sacral Neuromodulation (SNM) System for the treatment of urinary and fecal dysfunction, announced today that its first patients ...
New Orleans (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstracts: 293-OR, 240-OR Faster-acting insulin aspart improved postprandial glucose (PPG) control in type 1 and type 2 diabetes New phase 3a findings showed that ...
New Orleans (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstracts 87-LB and 90-LB New findings from the two phase 3b SWITCH trials showed that treatment with long-acting basal insulin Tresiba® (insulin degludec injection ...
Brussels (ots/PRNewswire) - For medical and trade media only. New data highlight breadth of UCB's pioneering portfolio with four molecules across five indications: - An oral presentation of data from the two year C-EARLY(TM) Phase 3 study of Cimzia®, exploring different dosing strategies - Oral presentations from ...
Amsterdam, The Netherlands (ots/PRNewswire) - In patients with IBD, CDI is a key risk factor for both morbidity and mortality, with disease interactions increasing the severity of patients' colitis[1] Results from an international consensus project involving a multidisciplinary group of clinicians have been ...
Boston (ots/PRNewswire) - For non-US medical media only. For journalistic assessment and preparation before publication. Oral Presentation# OR36-1 Today, new data from the three-year part of the phase 3a SCALE(TM) (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial were presented at ...